Search - tctmd.com

Displaying 1 - 20 of 44

Presentation TCT 2018

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

Presenter: David Erlinge, Gary S. Mintz, Martin W. Bergmann, Marc D. Feldman, Margaret B. McEntegart, Yasunori Ueda, Carlo Zivelonghi, Robert-Jan van Geuns

September 24, 2018

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

Presentation TCT 2018

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Duk-Woo Park

September 23, 2018

Presentation TCT 2018

De-Escalation of DAPT After DES Placement: Is There a Role for Personalized Treatment?

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Dániel Aradi

September 23, 2018

Presentation TCT 2018

GLOBAL LEADERS in Perspective: Perspectives on Ticagrelor Monotherapy

Presenter: Dominick J. Angiolillo, Elmir Omerovic, Patrick W. Serruys

September 23, 2018

Presentation TCT 2018

Managing Aspirin Allergy Before DES Placement

Presenter: Dominick J. Angiolillo, Elmir Omerovic, John A. Bittl

September 23, 2018

Presentation TCT 2018

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Presenter: Davide Capodanno, Giulio Stefanini, Robert A. Byrne

September 23, 2018

Presentation TCT 2018

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

Presenter: Davide Capodanno, Giulio Stefanini, Dominick J. Angiolillo

September 23, 2018

Presentation TCT 2018

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Presenter: Davide Capodanno, Giulio Stefanini, Freek W.A. Verheugt

September 23, 2018

Presentation TCT 2018

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Presenter: Davide Capodanno, Giulio Stefanini, C. Michael Gibson

September 23, 2018

Presentation TCT 2018

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

Presenter: Davide Capodanno, Giulio Stefanini, Tullio Palmerini

September 23, 2018

Presentation TCT 2018

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Presenter: Deepak L. Bhatt, Tullio Palmerini, Michael Maeng

September 23, 2018

Presentation TCT 2018

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Philip M. Urban

September 23, 2018

Presentation TCT 2018

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Usman Baber

September 23, 2018

Presentation TCT 2018

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Presenter: Martina Kelly Speight, Patricia Keegan

September 23, 2018

Presentation TCT 2018

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Presenter: Deepak L. Bhatt, Tullio Palmerini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2018

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

Presenter: John A. Bittl, C. Michael Gibson, Dimitrios Alexopoulos

September 23, 2018

Presentation TCT 2018

The Case for Bivalirudin With Radial (and Femoral) Access

Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel

September 23, 2018

Presentation TCT 2018

The Latest Antithrombotic Data: MATRIX at 1 Year

Presenter: John A. Bittl, C. Michael Gibson, Stephan Windecker

September 23, 2018

Advertisement

Case #5: A Case in Which I Used OCT to Reduce DAPT Duration

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

The Asian Anti-Platelet Therapy Paradox: Genetic Factors, Dosing, Bleeding, and Stent Thrombosis Risk

De-Escalation of DAPT After DES Placement: Is There a Role for Personalized Treatment?

GLOBAL LEADERS in Perspective: Perspectives on Ticagrelor Monotherapy

Managing Aspirin Allergy Before DES Placement

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

US and ESC Guidelines and Consensus on Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing PCI

In 2018 When Is Warfarin Therapy Required vs Acceptable, and How Should it Be Dosed After PCI?

Has PIONEER and REDUAL Changed My Practice? What Are the Outstanding Issues?

Pharmacotherapy Challenges and Possible Solutions in the PCI Patient on Chronic Oral Anticoagulation

COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI

Ultra-Short DAPT (1 3 Months): For Which Patients and Stents Do We Have Evidence?

Patient Selection for Prolonged DAPT: Risk Scores or Wise Clinical Judgement?

DAPT and Anticoagulation Post TAVR: What is the Standard of Care?

Who Is the High Bleeding Risk Patient, and How Should DAPT Duration Be Weighed Against Ischemic Risk?

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

How Strong are the Pharmacodynamic Data and Clinical Evidence for Crushed Ticagrelor and Prasugrel?

The Case for Bivalirudin With Radial (and Femoral) Access

The Latest Antithrombotic Data: MATRIX at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content